Rep. C. Scott Franklin Purchases Shares of Novo Nordisk A/S (NYSE:NVO)

Representative C. Scott Franklin (R-Florida) recently bought shares of Novo Nordisk A/S (NYSE:NVO). In a filing disclosed on August 14th, the Representative disclosed that they had bought between $15,001 and $50,000 in Novo Nordisk A/S stock on August 4th. The trade occurred in the Representative’s “FIDELITY TRADITIONAL IRA” account.

Representative C. Scott Franklin also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Comcast (NASDAQ:CMCSA) on 8/4/2025.
• Purchased $1,001 – $15,000 in shares of Novo Nordisk A/S (NYSE:NVO) on 8/4/2025.
• Sold $15,001 – $50,000 in shares of Comcast (NASDAQ:CMCSA) on 8/4/2025.
• Sold $1,001 – $15,000 in shares of United Parcel Service (NYSE:UPS) on 7/22/2025.
• Sold $50,001 – $100,000 in shares of United Parcel Service (NYSE:UPS) on 7/22/2025.
• Sold $15,001 – $50,000 in shares of Visa (NYSE:V) on 6/16/2025.
• Sold $15,001 – $50,000 in shares of Apple (NASDAQ:AAPL) on 6/16/2025.
• Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOG) on 6/16/2025.
• Sold $1,001 – $15,000 in shares of Merck & Co., Inc. (NYSE:MRK) on 6/16/2025.
• Sold $15,001 – $50,000 in shares of McDonald’s (NYSE:MCD) on 6/16/2025.

Novo Nordisk A/S Price Performance

NYSE:NVO opened at $53.81 on Tuesday. Novo Nordisk A/S has a 1-year low of $45.05 and a 1-year high of $139.74. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.52. The firm has a fifty day simple moving average of $64.52 and a 200 day simple moving average of $70.02. The stock has a market capitalization of $240.26 billion, a PE ratio of 14.78, a P/E/G ratio of 1.80 and a beta of 0.63.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.93 by $0.04. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The business had revenue of $11.69 billion during the quarter, compared to analysts’ expectations of $77.51 billion. On average, research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a semi-annual dividend, which will be paid on Tuesday, August 26th. Investors of record on Monday, August 18th will be paid a $0.4119 dividend. The ex-dividend date of this dividend is Monday, August 18th. This represents a dividend yield of 240.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 45.05%.

Analysts Set New Price Targets

A number of equities analysts have commented on NVO shares. Wall Street Zen cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Barclays reaffirmed an “equal weight” rating on shares of Novo Nordisk A/S in a research report on Wednesday, July 30th. BNP Paribas raised shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research report on Wednesday, August 13th. BNP Paribas Exane raised shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $54.00 price objective for the company in a research report on Wednesday, August 13th. Finally, UBS Group cut shares of Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 5th. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $83.75.

Institutional Investors Weigh In On Novo Nordisk A/S

A number of hedge funds and other institutional investors have recently modified their holdings of the company. N.E.W. Advisory Services LLC lifted its holdings in shares of Novo Nordisk A/S by 31.8% during the second quarter. N.E.W. Advisory Services LLC now owns 2,014 shares of the company’s stock worth $139,000 after buying an additional 486 shares in the last quarter. Rexford Capital Inc. acquired a new position in Novo Nordisk A/S in the second quarter valued at about $130,000. Parr Mcknight Wealth Management Group LLC raised its stake in Novo Nordisk A/S by 274.5% in the second quarter. Parr Mcknight Wealth Management Group LLC now owns 26,456 shares of the company’s stock valued at $1,826,000 after purchasing an additional 19,391 shares in the last quarter. Evergreen Capital Management LLC raised its stake in Novo Nordisk A/S by 13.2% in the second quarter. Evergreen Capital Management LLC now owns 171,348 shares of the company’s stock valued at $11,826,000 after purchasing an additional 19,955 shares in the last quarter. Finally, MayTech Global Investments LLC raised its stake in Novo Nordisk A/S by 5.9% in the second quarter. MayTech Global Investments LLC now owns 410,241 shares of the company’s stock valued at $26,662,000 after purchasing an additional 22,710 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

About Representative Franklin

Scott Franklin (Republican Party) is a member of the U.S. House, representing Florida’s 18th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Franklin (Republican Party) is running for re-election to the U.S. House to represent Florida’s 18th Congressional District. He declared candidacy for the 2026 election.

Scott Franklin was born in Thomaston, Georgia. Franklin graduated from Lakeland High School. He served in the U.S. Navy from 1986 to 2000 and the U.S. Navy Reserve from 2000 to 2012.

Franklin earned a B.S. from the United States Naval Academy in 1986 and an M.B.A. from Embry-Riddle Aeronautical University in 1994. Franklin’s career experience includes owning an insurance agency and working as a naval aviator with the U.S. Navy.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.